Title |
Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
|
---|---|
Published in |
Organic and Biomolecular Chemistry, January 2014
|
DOI | 10.1039/c3ob42428f |
Pubmed ID | |
Authors |
Mu Cheng, Zyta M. Ziora, Karl A. Hansford, Mark A. Blaskovich, Mark S. Butler, Matthew A. Cooper |
Abstract |
Dalbavancin, a semi-synthetic glycopeptide with enhanced antibiotic activity compared to vancomycin and teicoplanin, binds to the C-terminal lysyl-d-alanyl-d-alanine subunit of Lipid II, inhibiting peptidoglycan biosynthesis. In this study, micro-calorimetry and electrospray ionization (ESI)-MS have been used to investigate the relationship between oligomerisation of dalbavancin and binding of a Lipid II peptide mimic, diacetyl-Lys-d-Ala-d-Ala (Ac2-Kaa). Dalbavancin dimerised strongly in an anti-cooperative manner with ligand-binding, as was the case for ristocetin A, but not for vancomycin and teicoplanin. Dalbavancin and ristocetin A both adopt an 'closed' conformation upon ligand binding, suggesting anti-cooperative dimerisation with ligand-binding may be a general feature of dalbavancin/ristocetin A-like glycopeptides. Understanding these effects may provide insight into design of novel dalbavancin derivatives with cooperative ligand-binding and dimerisation characteristics that could enhance antibiotic activity. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 31% |
Student > Bachelor | 5 | 14% |
Student > Ph. D. Student | 5 | 14% |
Student > Postgraduate | 4 | 11% |
Student > Master | 3 | 8% |
Other | 2 | 6% |
Unknown | 6 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 10 | 28% |
Chemistry | 6 | 17% |
Agricultural and Biological Sciences | 6 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Medicine and Dentistry | 1 | 3% |
Other | 1 | 3% |
Unknown | 9 | 25% |